The buyer will have the option of deciding whether it wants to receive the rest. Before proceeding, we'll need to confirm you're of legal age in your province of residence. The company has a market capitalization of $293.71 million and a price-to-earnings ratio of -2.36. Organigram is one of many marijuana stocks facing a lawsuit. But just as quickly, gravity took hold of shares and mercilessly crated … The sector might be struggling, but OrganiGram stock remains a strong buy. It takes a lot of guts to stand by the besieged cannabis sector. Only half the sale is guaranteed; OrganiGram is obligated to deliver that much to Canndoc by Dec. 31, 2021. In 2019’s first quarter, OrganiGram reported a gross margin loss of 11.1 million CAD, indicating a sizable negative position. Canada's Marijuana Industry Has a New Problem, Copyright, Trademark and Patent Information. The company had revenue of C$18.02 million during the quarter, compared to analysts’ expectations of C$22.61 million. Organigram finished February with CA$41 million in cash after losing around CA$8 million during the first half of the company's fiscal year. The company also exports its products. Market data powered by FactSet and Web Financial Group. . David Moadel has provided compelling content – and crossed the occasional line – on behalf of Crush the Street, Market Realist, TalkMarkets, Finom Group, Benzinga, and (of course) InvestorPlace.com. Sales in the Canadian market declined and international revenue was minimal -- just CA$200,000. While the company notes that it has been supplying product to the Australian market, the opportunity to supply Israel and reach other markets through the deal with Canndoc could lead to much more sales growth down the road. In January 2019, the Middle Eastern country approved the export of medical marijuana, opening up opportunities for Israeli producers to ship to other countries nearby that have legalized cannabis for medical use. Yet, those are the most recent figures, and they’re highly encouraging for OrganiGram stockholders. Beauty Inc Expected to Post Q1 2023 Earnings of $0.08 Per Share (NYSE:ELF), John Wiley & Sons (NASDAQ:JW.B) Shares Down 1.1%, Direxion Daily Communication Services Index Bull 3X Shares (NYSEARCA:TAWK) Trading 6.5% Higher, Zacks: Brokerages Anticipate Jounce Therapeutics Inc (NASDAQ:JNCE) Will Post Earnings of -$0.78 Per Share, Direxion Daily Consumer Staples Bull 3X Shares (NYSEARCA:NEED) Stock Price Up 2.3%, -$0.06 Earnings Per Share Expected for Weidai Ltd (NYSE:WEI) This Quarter, BK IRELAND GRP/ADR (OTCMKTS:BKRIY) Shares Down 2.6%, Oi SA em Recuperacao Judicial (OTCMKTS:OIBRQ) Shares Down 4.4%, MarketBeat.com's FREE daily email newsletter, Head-To-Head Analysis: Norwegian Cruise Line vs. Its Rivals, Head-To-Head Comparison: Altus Midstream & Its Rivals, WP Carey Inc Given Average Recommendation of “Hold” by Brokerages, Zacks: Brokerages Expect Kimbell Royalty Partners LP Will Post Earnings of -$0.03 Per Share, Personal Group Releases Earnings Results, Contrasting Chaparral Energy & Its Competitors.